Susquehanna International Group
LPCN icon

Susquehanna International Group’s Lipocine LPCN Stock Holding History

Susquehanna International Group’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$199K Sell
24,908
-1
-0% -$9 ﹤0.01% 11717
2025
Q4 		$200K Sell
24,909
-21,852
-47% -$73.5K ﹤0.01% 10881
2025
Q3 		$134K Buy
46,761
+742
+2% +$2.25K ﹤0.01% 11373
2025
Q2 		$145K Buy
46,019
+7,039
+18% +$22.8K ﹤0.01% 11525
2025
Q1 		$124K Buy
38,980
+13,975
+56% +$54.1K ﹤0.01% 11379
2024
Q4 		$122K Sell
25,005
-3
-0% -$15 ﹤0.01% 11180
2024
Q3 		$112K Buy
25,008
+7
+0% +$35 ﹤0.01% 10973
2024
Q2 		$206K Sell
25,001
-34,666
-58% -$217K ﹤0.01% 10297
2024
Q1 		$310K Buy
59,667
+3,066
+5% +$11.9K ﹤0.01% 9634
2023
Q4 		$156K Buy
56,601
+31,272
+123% +$82.7K ﹤0.01% 10936
2023
Q3 		$74.5K Buy
25,329
+14,335
+130% +$60.3K ﹤0.01% 11109
2023
Q2 		$55K Buy
10,994
+4,149
+61% +$19.5K ﹤0.01% 11299
2023
Q1 		$37K Buy
6,845
+4,668
+214% +$36.1K ﹤0.01% 11828
2022
Q4 		$14.7K Buy
2,177
+118
+6% +$860 ﹤0.01% 11853
2022
Q3 		$16K Buy
2,059
+172
+9% +$1.92K ﹤0.01% 12671
2022
Q2 		$26K Buy
1,887
+128
+7% +$2K ﹤0.01% 12282
2022
Q1 		$41K Sell
1,759
-7,946
-82% -$166K ﹤0.01% 12392
2021
Q4 		$163K Buy
9,705
+7,370
+316% +$137K ﹤0.01% 11697
2021
Q3 		$43K Buy
+2,335
New +$51.5K ﹤0.01% 12396
2021
Q2 		– Sell
-8,454
Closed -$199K – 12961
2021
Q1 		$217K Buy
8,454
+3,152
+59% +$91K ﹤0.01% 11266
2020
Q4 		$123K Buy
+5,302
New +$128K ﹤0.01% 10381
2020
Q3 		– Sell
-2,729
Closed -$72.5K – 10883
2020
Q2 		$58K Buy
2,729
+2,078
+319% +$26.9K ﹤0.01% 9713
2020
Q1 		$5K Buy
+651
New +$5.15K ﹤0.01% 10106
2019
Q4 		– Sell
-2,328
Closed -$111K – 10230
2019
Q3 		$111K Buy
2,328
+1,019
+78% +$40.9K ﹤0.01% 9505
2019
Q2 		$43K Sell
1,309
-750
-36% -$23.1K ﹤0.01% 9875
2019
Q1 		$81K Buy
+2,059
New +$63.2K ﹤0.01% 8323
2018
Q4 		– Sell
-3,152
Closed -$74K – 9518
2018
Q3 		$74K Buy
3,152
+1,695
+116% +$41.7K ﹤0.01% 8714
2018
Q2 		$32K Buy
+1,457
New +$34.7K ﹤0.01% 9361
2017
Q1 		– Sell
-1,487
Closed -$96.4K – 9504
2016
Q4 		$93K Buy
+1,487
New +$94.1K ﹤0.01% 9119
2016
Q2 		– Sell
-4,054
Closed -$628K – 8986
2016
Q1 		$700K Buy
4,054
+1,214
+43% +$207K ﹤0.01% 5796
2015
Q4 		$624K Buy
+2,840
New +$596K ﹤0.01% 6347

Other funds holding LPCN

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
SFCM
Seven Fleet Capital Management Mountain View, California $318M AUM
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

Susquehanna International Group's LPCN Position: Q1 2026 in Review

Susquehanna International Group reduced its Lipocine (LPCN) stake by 0% in Q1 2026, selling an estimated $9 and leaving 24,908 shares worth $199K. The position accounts for ﹤0.01% of the portfolio, ranked #11717.

Susquehanna International Group first reported a position in LPCN in Q4 2015 and has held it in 31 quarters since. The position peaked at $700K in Q1 2016. 47 funds tracked by Wall St. Rank hold LPCN as of Q1 2026.

  • Susquehanna International Group held 24,908 shares of Lipocine worth $199K as of Q1 2026.
  • Susquehanna International Group sold 1 Lipocine share in Q1 2026, an estimated $9.
  • Lipocine made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #11717 holding.
  • Susquehanna International Group first reported a position in Lipocine in Q4 2015 and has held it in 31 quarters since.
  • Susquehanna International Group's Lipocine position peaked at $700K in Q1 2016.
  • 47 funds tracked by Wall St. Rank held Lipocine as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.